368 related articles for article (PubMed ID: 28326775)
1. Determining Cysteines Available for Covalent Inhibition Across the Human Kinome.
Zhao Z; Liu Q; Bliven S; Xie L; Bourne PE
J Med Chem; 2017 Apr; 60(7):2879-2889. PubMed ID: 28326775
[TBL] [Abstract][Full Text] [Related]
2. Identification of Covalent Binding Sites Targeting Cysteines Based on Computational Approaches.
Zhang Y; Zhang D; Tian H; Jiao Y; Shi Z; Ran T; Liu H; Lu S; Xu A; Qiao X; Pan J; Yin L; Zhou W; Lu T; Chen Y
Mol Pharm; 2016 Sep; 13(9):3106-18. PubMed ID: 27483186
[TBL] [Abstract][Full Text] [Related]
3. Leveraging Compound Promiscuity to Identify Targetable Cysteines within the Kinome.
Rao S; Gurbani D; Du G; Everley RA; Browne CM; Chaikuad A; Tan L; Schröder M; Gondi S; Ficarro SB; Sim T; Kim ND; Berberich MJ; Knapp S; Marto JA; Westover KD; Sorger PK; Gray NS
Cell Chem Biol; 2019 Jun; 26(6):818-829.e9. PubMed ID: 30982749
[TBL] [Abstract][Full Text] [Related]
4. Assessing Lysine and Cysteine Reactivities for Designing Targeted Covalent Kinase Inhibitors.
Liu R; Yue Z; Tsai CC; Shen J
J Am Chem Soc; 2019 Apr; 141(16):6553-6560. PubMed ID: 30945531
[TBL] [Abstract][Full Text] [Related]
5. The Cysteinome of Protein Kinases as a Target in Drug Development.
Chaikuad A; Koch P; Laufer SA; Knapp S
Angew Chem Int Ed Engl; 2018 Apr; 57(16):4372-4385. PubMed ID: 28994500
[TBL] [Abstract][Full Text] [Related]
6. Targeting protein kinases with selective and semipromiscuous covalent inhibitors.
Miller RM; Taunton J
Methods Enzymol; 2014; 548():93-116. PubMed ID: 25399643
[TBL] [Abstract][Full Text] [Related]
7. Developing irreversible inhibitors of the protein kinase cysteinome.
Liu Q; Sabnis Y; Zhao Z; Zhang T; Buhrlage SJ; Jones LH; Gray NS
Chem Biol; 2013 Feb; 20(2):146-59. PubMed ID: 23438744
[TBL] [Abstract][Full Text] [Related]
8. Conformational analysis of the DFG-out kinase motif and biochemical profiling of structurally validated type II inhibitors.
Vijayan RS; He P; Modi V; Duong-Ly KC; Ma H; Peterson JR; Dunbrack RL; Levy RM
J Med Chem; 2015 Jan; 58(1):466-79. PubMed ID: 25478866
[TBL] [Abstract][Full Text] [Related]
9. Controlling the Covalent Reactivity of a Kinase Inhibitor with Light.
Reynders M; Chaikuad A; Berger BT; Bauer K; Koch P; Laufer S; Knapp S; Trauner D
Angew Chem Int Ed Engl; 2021 Sep; 60(37):20178-20183. PubMed ID: 34081840
[TBL] [Abstract][Full Text] [Related]
10. How Reactive are Druggable Cysteines in Protein Kinases?
Awoonor-Williams E; Rowley CN
J Chem Inf Model; 2018 Sep; 58(9):1935-1946. PubMed ID: 30118220
[TBL] [Abstract][Full Text] [Related]
11. Cysteine mapping in conformationally distinct kinase nucleotide binding sites: application to the design of selective covalent inhibitors.
Leproult E; Barluenga S; Moras D; Wurtz JM; Winssinger N
J Med Chem; 2011 Mar; 54(5):1347-55. PubMed ID: 21322567
[TBL] [Abstract][Full Text] [Related]
12. Selectively Targeting the Kinome-Conserved Lysine of PI3Kδ as a General Approach to Covalent Kinase Inhibition.
Dalton SE; Dittus L; Thomas DA; Convery MA; Nunes J; Bush JT; Evans JP; Werner T; Bantscheff M; Murphy JA; Campos S
J Am Chem Soc; 2018 Jan; 140(3):932-939. PubMed ID: 29232121
[TBL] [Abstract][Full Text] [Related]
13. Development of covalent inhibitors that can overcome resistance to first-generation FGFR kinase inhibitors.
Tan L; Wang J; Tanizaki J; Huang Z; Aref AR; Rusan M; Zhu SJ; Zhang Y; Ercan D; Liao RG; Capelletti M; Zhou W; Hur W; Kim N; Sim T; Gaudet S; Barbie DA; Yeh JR; Yun CH; Hammerman PS; Mohammadi M; Jänne PA; Gray NS
Proc Natl Acad Sci U S A; 2014 Nov; 111(45):E4869-77. PubMed ID: 25349422
[TBL] [Abstract][Full Text] [Related]
14. Irreversible protein kinase inhibitors.
Garuti L; Roberti M; Bottegoni G
Curr Med Chem; 2011; 18(20):2981-94. PubMed ID: 21651479
[TBL] [Abstract][Full Text] [Related]
15. Profiling MAP kinase cysteines for targeted covalent inhibitor design.
Liu R; Verma N; Henderson JA; Zhan S; Shen J
RSC Med Chem; 2022 Jan; 13(1):54-63. PubMed ID: 35224496
[TBL] [Abstract][Full Text] [Related]
16. An electrophilic warhead library for mapping the reactivity and accessibility of tractable cysteines in protein kinases.
Petri L; Egyed A; Bajusz D; Imre T; Hetényi A; Martinek T; Ábrányi-Balogh P; Keserű GM
Eur J Med Chem; 2020 Dec; 207():112836. PubMed ID: 32971426
[TBL] [Abstract][Full Text] [Related]
17. Affinity reagents that target a specific inactive form of protein kinases.
Ranjitkar P; Brock AM; Maly DJ
Chem Biol; 2010 Feb; 17(2):195-206. PubMed ID: 20189109
[TBL] [Abstract][Full Text] [Related]
18. A road map to evaluate the proteome-wide selectivity of covalent kinase inhibitors.
Lanning BR; Whitby LR; Dix MM; Douhan J; Gilbert AM; Hett EC; Johnson TO; Joslyn C; Kath JC; Niessen S; Roberts LR; Schnute ME; Wang C; Hulce JJ; Wei B; Whiteley LO; Hayward MM; Cravatt BF
Nat Chem Biol; 2014 Sep; 10(9):760-767. PubMed ID: 25038787
[TBL] [Abstract][Full Text] [Related]
19. Orally effective FDA-approved protein kinase targeted covalent inhibitors (TCIs).
Roskoski R
Pharmacol Res; 2021 Mar; 165():105422. PubMed ID: 33434619
[TBL] [Abstract][Full Text] [Related]
20. Therapeutic Targeting the Allosteric Cysteinome of RAS and Kinase Families.
Li L; Meyer C; Zhou ZW; Elmezayen A; Westover K
J Mol Biol; 2022 Sep; 434(17):167626. PubMed ID: 35595166
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]